SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2012 / Cilt: 50 - Sayı: 1

Adalimumab kullanımının tetiklediği sistemik lupus eritematozus

Adalimumab induced systemic lupus erythematosus

SONGÜL ÇİLDAĞ
TAŞKIN ŞENTÜRK
Pages
27–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Despite good clinical efficacy and tolerance, the possible occurrence of druginduced autoimmune disorders remains a matter of concern.The incidence of anti-tumor necrosis factor-alpha therapy induced autoimmune disorders is unknown.We report a new case of adalimumab-induced lupus syndrome with rheumatoid arthritis. (The Me di cal Bul le tin of Ha se ki 2012; 50: 27-9)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tumour necrosis factor alpha is a pivotal cytokine involved in the pathogenesis and progression of rheumatoid arthritis.
📊
Key Findings & Data:Anti-tumor necrosis factor-alpha therapy has become a very important modality in the treatment of patients with rheumatoid arthritis.
💡
Conclusion & Impact:Despite good clinical efficacy and tolerance, the possible occurrence of druginduced autoimmune disorders remains a matter of concern.The incidence of anti-tumor necrosis factor-alpha therapy induced autoimmune disorders is unknown.We report a new case of adalimumab-induced lupus syndrome with rheumatoid arthritis. (The Me di cal Bul le tin of Ha se ki 2012; 50: 27-9)
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Tumour necrosis factor alpha is a pivotal cytokine involved in the pathogenesis and progression of rheumatoid arthritis. Anti-tumor necrosis factor-alpha therapy has become a very important modality in the treatment of patients with rheumatoid arthritis. Despite good clinical efficacy and tolerance, the possible occurrence of druginduced autoimmune disorders remains a matter of concern.The incidence of anti-tumor necrosis factor-alpha therapy induced autoimmune disorders is unknown.We report a new case of adalimumab-induced lupus syndrome with rheumatoid arthritis. (The Me di cal Bul le tin of Ha se ki 2012; 50: 27-9)

Özet

Tümör nekrozis faktör alfa, romatoid artrit patogenezinde ve progresyonunda yer alan önemli bir sitokindir. Romatoid artritli hastaların tedavisinde anti tümör nekrozis faktör alfa oldukça önemli bir tedavi seçneğidir. İyi tolere edilmesi ve etkinliğinin iyi olmasına rağmen ilacın tetiklediği otoimmün hastalıklar endişe yaratmaktadır. Anti tümör nekrozis faktör alfa kullanımına bağlı otoimmün hastalık gelişim insidansı bilinmemektedir. Bu çalışmada adalimumab kullanımı sonrasında lupus gelişen romatoid artritli bir olgu sunulmuştur (Ha se ki T›p Bül te ni 2012; 50: 27-9)

🔖

Cite This Article

ÇİLDAĞ, S., ŞENTÜRK, T. (2012). Adalimumab kullanımının tetiklediği sistemik lupus eritematozus. Haseki Tıp Bülteni, Cilt: 50 - Sayı: 1, 27–29. https://ajindex.com/articles/267975

References (16)

  1. Lundy SK, Sarkar S, Tesmer LA, Fox D. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther 2007;9:202
  2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60
  3. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16
  4. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61
  5. Garrison L, McDonnell N. Etanercept therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58(suppl 1):165-9
  6. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9
  7. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Current Opinion in Rheumatology 2006;18:96-100
  8. Bobbio-Pallavicini F, Alpini C, Caporali R, et al. Montecucco Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004,6:R264-72
  9. De Bandt M, Vittecoq O, Descamps V, et al. Anti-TNF alpha-induced systemic lupus erythematosus. Clin Rheumatol 2003;22:56-61
  10. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80
  11. Lee H-H, Song I-H, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists. Br J Dermatol 2007;156:486-91
  12. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNF-promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6
  13. Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4:637-41
  14. Martín JM, Ricart JM, Alcácer J, Rausell N, Arana G. Adalimumabinduced lupus erythematosus. Lupus 2008;17:676-8
  15. Hess E. Drug-induced lupus. N Engl J Med 1988;318:1460-2
  16. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by an